158 related articles for article (PubMed ID: 10608481)
41. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine.
Isohanni MH; Neuvonen PJ; Palkama VJ; Olkkola KT
Eur J Clin Pharmacol; 1998 Sep; 54(7):561-5. PubMed ID: 9832299
[TBL] [Abstract][Full Text] [Related]
42. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone.
Korhonen T; Turpeinen M; Tolonen A; Laine K; Pelkonen O
J Steroid Biochem Mol Biol; 2008 May; 110(1-2):56-66. PubMed ID: 18356043
[TBL] [Abstract][Full Text] [Related]
43. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man.
Becquemont L; Le Bot MA; Riche C; Funck-Brentano C; Jaillon P; Beaune P
Pharmacogenetics; 1998 Apr; 8(2):101-8. PubMed ID: 10022747
[TBL] [Abstract][Full Text] [Related]
44. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
45. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
46. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.
Härtter S; Wang X; Weigmann H; Friedberg T; Arand M; Oesch F; Hiemke C
J Clin Psychopharmacol; 2001 Apr; 21(2):167-74. PubMed ID: 11270913
[TBL] [Abstract][Full Text] [Related]
47. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
von Moltke LL; Durol AL; Duan SX; Greenblatt DJ
Eur J Clin Pharmacol; 2000 Jun; 56(3):259-61. PubMed ID: 10952482
[TBL] [Abstract][Full Text] [Related]
48. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Pharmacol Toxicol; 1999 Mar; 84(3):143-6. PubMed ID: 10193676
[TBL] [Abstract][Full Text] [Related]
49. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes.
Jang GR; Wrighton SA; Benet LZ
Biochem Pharmacol; 1996 Sep; 52(5):753-61. PubMed ID: 8765473
[TBL] [Abstract][Full Text] [Related]
50. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
[TBL] [Abstract][Full Text] [Related]
51. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
von Moltke LL; Greenblatt DJ; Court MH; Duan SX; Harmatz JS; Shader RI
J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
54. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1.
Gallagher EP; Wienkers LC; Stapleton PL; Kunze KL; Eaton DL
Cancer Res; 1994 Jan; 54(1):101-8. PubMed ID: 8261428
[TBL] [Abstract][Full Text] [Related]
55. Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites.
Oda Y; Kharasch ED
J Pharmacol Exp Ther; 2001 Apr; 297(1):410-22. PubMed ID: 11259570
[TBL] [Abstract][Full Text] [Related]
56. Biotransformation of fluticasone: in vitro characterization.
Pearce RE; Leeder JS; Kearns GL
Drug Metab Dispos; 2006 Jun; 34(6):1035-40. PubMed ID: 16565171
[TBL] [Abstract][Full Text] [Related]
57. Effect of phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3-hydroxylidocaine in the rat: correlation with P450 isoform levels.
Nakamoto T; Oda Y; Imaoka S; Funae Y; Fujimori M
Drug Metab Dispos; 1997 Mar; 25(3):296-300. PubMed ID: 9172946
[TBL] [Abstract][Full Text] [Related]
58. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.
Schmider J; Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI
J Pharmacol Exp Ther; 1995 Nov; 275(2):592-7. PubMed ID: 7473143
[TBL] [Abstract][Full Text] [Related]
59. Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.
Wang JS; Wen X; Backman JT; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Oct; 85(4):157-61. PubMed ID: 10563513
[TBL] [Abstract][Full Text] [Related]
60. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
May-Manke A; Kroemer H; Hempel G; Bohnenstengel F; Hohenlöchter B; Blaschke G; Boos J
Cancer Chemother Pharmacol; 1999; 44(4):327-34. PubMed ID: 10447581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
